Medication Complications in Extracorporeal Membrane Oxygenation.

Authors

Ami G. Shah, Thomas Jefferson UniversityFollow
Michelle Peahota, Thomas Jefferson UniversityFollow
Brandi Thoma, Thomas Jefferson UniversityFollow
Walter K. Kraft, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

10-1-2017

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Critical Care Clinics

Volume 33, Issue 4, October 2017, Pages 897–920.

The published version is available at DOI: 10.1016/j.ccc.2017.06.010. Copyright © Elsevier

Abstract

The need for extracorporeal membrane oxygenation (ECMO) therapy is a marker of disease severity for which multiple medications are required. The therapy causes physiologic changes that impact drug pharmacokinetics. These changes can lead to exposure-driven decreases in efficacy or increased incidence of side effects. The pharmacokinetic changes are drug specific and largely undefined for most drugs. We review available drug dosing data and provide guidance for use in the ECMO patient population.

Recommended Citation

Shah, Ami G.; Peahota, Michelle; Thoma, Brandi; and Kraft, Walter K., "Medication Complications in Extracorporeal Membrane Oxygenation." (2017). College of Pharmacy Faculty Papers. Paper 31.
https://jdc.jefferson.edu/pharmacyfp/31

PubMed ID

28887935